BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34475067)

  • 1. Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Masuda H; Fujimoto A; Kanesaka M; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    Anticancer Res; 2021 Sep; 41(9):4443-4446. PubMed ID: 34475067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer.
    Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    In Vivo; 2021; 35(6):3489-3493. PubMed ID: 34697186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Masuda H
    Anticancer Res; 2023 Jan; 43(1):305-309. PubMed ID: 36585176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Hypertension on Early Renal Dysfunction in Japanese Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Masuda H; Sugiura M; Hou K; Araki K; Kojima S; Naya Y
    Cancer Diagn Progn; 2021; 1(3):179-183. PubMed ID: 35399311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    In Vivo; 2018; 32(2):409-412. PubMed ID: 29475929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
    Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
    Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
    Girard D; Marino FE; Cannon J
    Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
    Fujimoto N; Kubo T; Tomisaki I
    Clin Genitourin Cancer; 2015 Aug; 13(4):359-363. PubMed ID: 25907231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer.
    Roy S; Grimes S; Eapen L; Spratt DE; Malone J; Craig J; Morgan SC; Malone S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1179-1188. PubMed ID: 32565318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
    Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
    JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.